Panel talk about Inify’s third quarter 2024

Inify Laboratories have decided to establish its operation to the United Kingdom and expand diagnostics to the gastrointestinal field. One of the major challenges in the UK is long and unpredictable response times and varying quality in prostate cancer care. The market is six times larger than Sweden´s in terms of patient volume, with approximately 120,000 patients annually who require diagnosis.

"The national health care system NHS in the UK has a high focus on pathways for patients that are going through cancer investigations, and here is exactly where we provide unique value" says Inify´s CEO Fredrik Palm. More details about the geographical expansion and the gastrointestinal diagnostics are discussed in the panel talk led by Ole Eikeland with CEO Fredrik Palm.

Link to the panel talk is available here.

For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.